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AntibioticsThe genus Streptococcus contains 104 recognized species, many of which are associated with human or
animal hosts. A globally prevalent human pathogen in this group is Streptococcus pneumoniae (the
pneumococcus). While being a common resident of the upper respiratory tract, it is also a major cause
of otitis media, pneumonia, bacteremia and meningitis, accounting for a high burden of morbidity and
mortality worldwide. Recent ﬁndings demonstrate the importance of recombination and selection in
driving the population dynamics and evolution of different pneumococcal lineages, allowing them to
successfully evade the impacts of selective pressures such as vaccination and antibiotic treatment. We
highlight the ability of pneumococci to respond to these pressures through processes including serotype
replacement, capsular switching and horizontal gene transfer (HGT) of antibiotic resistance genes. The
challenge in controlling this pathogen also lies in the exceptional genetic and phenotypic variation
among different pneumococcal lineages, particularly in terms of their pathogenicity and resistance to
current therapeutic strategies. The widespread use of pneumococcal conjugate vaccines, which target
only a small subset of the more than 90 pneumococcal serotypes, provides us with a unique opportunity
to elucidate how the processes of selection and recombination interact to generate a remarkable level of
plasticity and heterogeneity in the pneumococcal genome. These processes also play an important role in
the emergence and spread of multi-resistant strains, which continues to pose a challenge in disease
control and/or eradication. The application of population of genomic approaches at different spatial
and temporal scales will help improve strategies to control this global pathogen, and potentially other
pathogenic streptococci.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Gray, 1998; Rubins et al., 2008). The introduction of conjugate vac-The genus Streptococcus is a diverse group of 104 recognized
species (http://www.bacterio.cict.fr/s/streptococcus.html as of July
21, 2014), whose interactions with host organisms vary from com-
mensal to pathogenic. Many of the pathogenic species cause
severe, invasive infections that account for a high burden of mor-
bidity and mortality (Gray, 1998; Mitchell, 2003), associated with
high economic and health care costs. One of the most clinically rel-
evant Streptococcus species colonizing humans is Streptococcus
pneumoniae (or pneumococcus), whose control remains a chal-
lenge despite the availability of highly effective vaccines. The
pneumococcus is a quiescent colonizer of the upper respiratory
tract and is carried asymptomatically by a fraction of the popula-
tion, ranging from 21% to 94% in high burden settings such as
Sub-Saharan Africa (Usuf et al., 2014). However, it can cause dis-
eases such as otitis media, conjunctivitis, pneumonia, bacteremia
and meningitis. Pneumococcal diseases are most prevalent in chil-
dren, the elderly and immuno-compromised (French et al., 2007;cination in children worldwide has had profound consequences for
the burden of pneumococcal diseases as well as the population
structure of carriage and invasive strains. However, the efﬁcacy
of these control measures has been limited by the pneumococcus’
exceptional ability to circumvent them. Years after the introduc-
tion of the ﬁrst pneumococcal conjugate vaccine (PCV) in 2000,
we are beginning to understand the long-term impact of these
vaccines.
Genomic methods have made an important contribution to our
understanding of the biology and epidemiology of important bac-
terial pathogens, including the pneumococcus. Molecular methods
historically important in pneumococcal epidemiology, and still
widely used today, include multi-locus sequence typing (MLST)
(Enright and Spratt, 1998), in which seven housekeeping genes
are sequenced as a sample of genomic variation and are used to
deﬁne the sequence type (ST). Another example of an historically
important molecular method is pulsed ﬁeld gel electrophoresis
(PFGE) in which strains are distinguished on the basis of restriction
digestion of their genomic DNA (Lefevre et al., 1993). Differences in
the numbers and location of the restriction sites are then visual-
ized by electrophoresis. By investigating genetic and phenotypic
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cidate the pace and patterns of pneumococcal diversiﬁcation. The
control of pneumococcal disease depends on our ability to antici-
pate the ways in which the organism responds to interventions,
and genomic methods provide the best, most extensive data for
the study of pneumococcal evolution.
While genomics is a rapidly changing ﬁeld, as of this writing,
the pneumococcus can lay claim to be the best-studied organism
from a population genomic standpoint, with multiple large sam-
ples already published (Chewapreecha et al., 2014; Croucher
et al., 2014a, 2013). In this review, we discuss recent ﬁndings in
pneumococcal genome evolution, with a focus on the roles of
recombination and selection. We highlight the impacts of vac-
cine-induced selective pressures in driving the population dynam-
ics and evolution of different pneumococcal lineages. We also
discuss how the pneumococci respond to these pressures, mainly
through recombination within the species as well as with other
Streptococci. The contributions of mobile elements and phages to
pneumococcal evolution will also be discussed. We conclude with
future directions on how genomics can enhance our understanding
of the role of vaccination and antibiotic use in pneumococcal evo-
lution and disease control.2. The promiscuous pneumococcus
2.1. Pneumococcal diversity, transformation and recombination
Pneumococci are competent and naturally transformable, mean-
ing that they readily take up exogenous DNA and can incorporate it
into the genome by homologous recombination. This is not rare; a
study of a single lineage [designated PMEN1 by the Pneumococcal
Molecular Epidemiology Network (McGee et al., 2001)] estimated
that 74% of its genome had been altered by recombination in at
least one isolate in a sample estimated to have diversiﬁed from a
most recent common ancestor in the early 1970s (Croucher et al.,
2011). This was the result of a study of a global sample, but at the
opposite scale, a study of six isolates obtained within a seven-
month period from the same individual found a remarkable 23
recombination replacements (Hiller et al., 2010), resulting in the
replacement of 7.8% of the genome. Horizontal transfer of genetic
material in general, not only by homologous recombination but also
bymobile genetic elements, can substantially amplify the heteroge-
neity of the common gene pool of the pneumococcus, as was
observed in the study of PMEN1 isolates retrieved between 1994
and 2008 mentioned above. In this work, recombinant regions var-
ied in size from 3 bp to 72,038 bp (Croucher et al., 2011). Such high
levels of recombination ensure the success of a clone over the long
term, particularly in the face of environmental changes, as was
reported for the multi-drug resistant PMEN2 that predominated
in Iceland in the 1990s. The decline in its prevalence following
the reduction in antibiotic use was largely due to the lack of
sequence import through recombination that prevented the modi-
ﬁcation of core sequences associated with resistance and antigenic
diversiﬁcation (Croucher et al., 2014b).
Although the pneumococcus is known to be highly transform-
able and recombining, there is marked variation in these traits
among isolates. An experimental study showed variation over four
orders of magnitude (102 to 106) in transformation frequencies
in isolates from asymptomatic carriage, and this variation does
not correlate with genetic relatedness of isolates (Evans and
Rozen, 2013). The causes of this variation, whether essential
(resulting from differences in the mechanism of DNA uptake) or
ecological (recombination is limited by the isolates rarely encoun-
tering one another in nature), remain poorly understood. One pos-
sible explanation is that these observed differences might beattributed to the environmental stresses faced by different pneu-
mococcal lineages. Chemostat evolution experiments of the costs
and beneﬁts of transformation in pneumococcus grown for 1000
generations demonstrate that transformation can beneﬁt cells liv-
ing in stressful environments and can be costly in benign environ-
ments (Engelmoer et al., 2013). Rather than being selected by
stress, recombination may be directly linked to it through the over-
lap of the stress response with the competence pathway responsi-
ble for taking up DNA (Dagkessamanskaia et al., 2004). It is easy to
understand how interactions with the immune system, as well as
interventions such as antimicrobials and vaccines, could create a
stressful environment for the pathogen.
Different pneumococcal lineages also demonstrate signiﬁcant
variation in recombination rates, measured as the rate at which
nucleotide polymorphisms accumulate through recombination rel-
ative to mutation (r/m). For example, whole genome analyses of
carried pneumococci from Massachusetts showed a wide range
of recombination rates, with the highest value associated with a
clade containing the highly resistant ST 320 and which has prolif-
erated following vaccination despite originally having a vaccine
serotype. The loci determining serotype have been replaced with
those of a non-vaccine serotype (NVT) by recombination. This pro-
cess, which can generate novel combinations of serotype and geno-
mic backbone, is known as capsular switching (Croucher et al.,
2013). Recombination, however, is not uniform throughout the
pneumococcal population. It has been recently described to consist
of two modes of action: micro-recombinations involve the fre-
quent replacement of single, short DNA fragments, and macro-
recombinations, though rarer, involve the acquisition of multiple,
long fragments and is a associated with major phenotypic changes
(Mostowy et al., 2014).
In addition to variation in the uptake of DNA, some strains exhi-
bit propensity to either donate or receive exogenous DNA more
often than others. Chewapreecha et al. (2014) found that a lineage
of pneumococci in their sample that lacked a capsule was more
likely to both gain and donate DNA to other lineages. Again, a study
of isolates from a single chronic childhood infection showed simi-
lar variation at the level of evolution within a single host (Hiller
et al., 2010). During this time period, one particular strain, ST
2011v4, donated DNA extensively to the other infecting strains,
all of which are closely related ST 13 strains. Unambiguously iden-
tifying donors is not easy, because in a recombinogenic organism
like the pneumococcus, the sequence in question may be found
in multiple lineages and the ultimate origin is hard to deﬁne. It is
reasonable to think that some lineages may donate more often
than others, if for no other reason than that some lineages are more
commonly found in the population than others, and so will have
more opportunity [(for instance, it is not clear the unencapsulated
lineage discussed above (Chewapreecha et al., 2014) is a more
common donor or recipient than one would expect given its fre-
quency in the population]. Moreover, lineages that are over repre-
sented in a sample may be more readily identiﬁed as donors or
recipients, and it is important to recognize such possible bias.
The consequences of variation in recombination can be impor-
tant; pneumococci with evidence of extensive recombination at
housekeeping loci are signiﬁcantly associated with antibiotic resis-
tance (Hanage et al., 2009). Genomic sequencing in diverse envi-
ronmental backgrounds can therefore help us deﬁne the causes
and consequences of the variation in transformation, recombina-
tion and other phenotypic traits in pneumococcus.
2.2. Gene gain across species boundaries
The ability of the pneumococcus to donate and receive genetic
material is not restricted to its own species. Novel genes can be
acquired from other taxa, many of which also inhabit the same
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mococcus, indicating that a shared habitat can greatly facilitate
inter-species mobilization of genes (Muzzi and Donati, 2011). Hor-
izontal gene transfer (HGT) that traverses boundaries of tradition-
ally named species can enhance the pneumococcal gene pool and
lead to exceptionally variable genomes of individual isolates. Other
streptococcal species, such as Streptococcus mitis, Streptococcus
infantis and Streptococcus oralis, are frequent exchange partners
of pneumococcus (Donati et al., 2010). Genomic comparisons
between these streptococcal species indicate that 30% of the
sequence variability, which also includes pathogenicity genes, in
pneumococcus is shared with S. mitis, making it an external genetic
reservoir for the pneumococcus (Donati et al., 2010; Sanguinetti
et al., 2012). HGT may also explain the large number of pneumo-
coccal virulence genes, such as those encoding for pneumolysin,
mitilysin and neuraminidase A, found in other members of the
mitis group of Streptococci (Johnston et al., 2010). Frequent genetic
transfer between and within streptococcal species can contribute
to a rapid response to diverse and/or ﬂuctuating environments,
which are particularly useful for pathogens frequently bombarded
with antibiotics. For example, large imports of genes from S. mitis
and other mitis, anginosus, and salivarius group streptococci to
the pneumococcus have been reported to contribute to the evolu-
tion and structural diversity of the pneumococcal capsule (Kilian
et al., 2014).3. Pneumococcal strategies against vaccine-induced selection
pressures
3.1. Pneumococcal conjugate vaccines (PCVs)
The primary virulence determinant of pneumococcus is its
anti-phagocytic polysaccharide capsule. The capsular locus (cps)
is transcribed as a single operon and all strains exhibit a similar
organization with the genes coding for a speciﬁc capsule ﬂanked
by other genes (dexB and aliA) common to all strains (Bentley
et al., 2006; García et al., 1999). Multiple and subtle polymor-
phisms in the capsular operon result in serologically distinct vari-
ants (or serotypes), of which there are currently 94 identiﬁed
(Bentley et al., 2006; Bratcher et al., 2011). The serotypes vary con-
siderably in carriage rates, disease potential, geographical distribution
and the prevalence of antibiotic resistance (Hausdorff et al., 2008).
PCVs are composed of capsular polysaccharides chemically
linked to a carrier protein, making them more immunogenic in
young children. Only a subset of these has been included in current
vaccines. PCVs for routine immunization of infants and children
started with PCV7, which was introduced in the US in 2000 (which
targeted the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and subse-
quently replaced with PCV13 in 2010 (for serotypes 1, 3, 5, 6A, 7F,
19A in addition to the PCV7 serotypes). These were designed to tar-
get the most dominant serotypes involved in invasive pneumococ-
cal diseases in children; while PCV7 was targeted at the most
common causes of disease in the US and Europe, PCV13 has
expanded coverage to include serotypes like 1 and 5 that are
important and frequent causes of disease in the rest of the world,
especially sub-Saharan Africa (Hausdorff et al., 2000a,b). Other vac-
cines have also been manufactured, including PCV10 (for serotypes
1, 5 and 7F in addition to the PCV7 serotypes) and PPSV23 (for 23
serotypes; contains unattached polysaccharide antigens), with the
latter approved for use in adults and patients with speciﬁc risk fac-
tors who are at least 2 years old. Conjugate vaccines are highly
effective at preventing invasive disease (Dagan and Klugman,
2008; Feldman and Anderson, 2014), but the pneumococcus con-
tinues to be a formidable foe. Its ability to circumvent these selec-
tive pressures lies in its highly variable genome and intra-speciesdiversity. Advances in the development of new generation vaccines
focusing on recombinant protein and whole cell vaccines have the
potential to provide serotype-independent protection. Such vac-
cines would provide an alternative, or at least complement, exist-
ing capsule-based vaccines in controlling drug resistance and
eradicating pneumococcal diseases.
3.2. Serotype replacement
With the elimination of previously dominant serotypes due to
vaccine selection, expansion of NVTs can occur as they take advan-
tage of the removal of competition from the vaccine types (VT).
While there was initially some concern that changes in the preva-
lence of NVT could be ‘secular trends’ unrelated to the vaccine, it is
now accepted that the increase in NVT has been too widespread
and universally observed to be independent of PCV7. This popula-
tion level change in the serotype distribution, most often involving
pre-existing clones and serotypes that were already in circulation
before vaccine implementation, is known as serotype replacement.
In the United States, prevalence of PCV7 serotypes in all age groups
decreased from 64% of invasive and 50% of noninvasive isolates in
1999–2000 to 3.8% and 4.2%, respectively, in 2010–2011 (Richter
et al., 2013). After the initial PCV7 immunization, the diversity
and population structure of carriage pneumococci was also altered
(Hanage et al., 2010), even though the overall carriage prevalence
has remained constant (Hanage et al., 2011; Wroe et al., 2012).
Similar outcomes have been reported in Asia (Kim et al., 2012;
Song et al., 2009), Australia (Lehmann et al., 2010), Africa
(Nzenze et al., 2013) and Europe (Hanquet et al., 2010; Pichon
et al., 2013). This observed decrease could be attributed to both
direct vaccine effect and herd immunity in the community.
The most noteworthy example of serotype replacement in the
PCV7 era was the dramatic increase in the prevalence of serotype
19A. While it was initially anticipated that the serotype 19F com-
ponent of PCV7 would provide cross-protection against 19A, this
was not the case. In fact, 19A replacement occurred rapidly follow-
ing high vaccine coverage. Initially, the majority of 19A in both car-
riage and disease were the result of the clonal expansion of one
genotype, ST 199, already common prior to the introduction of
PCV7 (Beall et al., 2011; Moore et al., 2008; Pai et al., 2005; Scott
et al., 2012a). However, in time multiple unrelated genotypes were
also found in increasing numbers, some of which exhibited high-
level resistance to multiple antibiotics, as in the case of the globally
successful ST 320 (Clarke et al., 2004). ST 320 is an example of a
lineage that is the product capsular switching, having originally
been found with a PCV7 serotype: 19F. The 19A variant of this line-
age was able to evade the vaccine and prosper. ST 320 has also
been noted to have a very high rate of recombination across the
genome (Croucher et al., 2013), which might plausibly contribute
to its success in adapting to the post vaccine era. Another notable
case is the replacement of 23F with relatives from 23A and 23B of
the same serogroup (Croucher et al., 2013). Competitive interac-
tions between strains, particularly in terms of colonization, are
likely to drive serotype replacement in pneumococci (Mehtälä
et al., 2013).
While the long-term impacts of PCV13 on pneumococcal popu-
lation structure and serotype composition remain to be seen, initial
observations suggest patterns comparable to those observed for
PCV7 (Kaplan et al., 2013). In carriage, although colonization with
non-PCV13 serotypes appears to be increasing, the rate of overall
pneumococcal colonization was not affected (Lee et al., 2014). In
particular, the prevalence of the non-PCV13 serotype 35B appears
to be increasing in both invasive and non-invasive diseases
(Richter et al., 2013).
Population genomic studies have allowed us to chart how the
changing epidemiological and selective landscape imposed by vac-
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alence of speciﬁc donors and recipients may also subsequently
affect the genomic composition of individual serotypes. Whole
genome analyses can provide insights into the long-term and
broader impacts of serotype replacement, particularly in terms of
the variation in the ecology and pathogenesis of different
serotypes.
3.3. Capsular switching
In pneumococci, genetic exchange at the capsular locus is
greatly facilitated by the syntenic organization and homology of
genes in the capsular locus (Hu et al., 2012). This process of substi-
tuting the genes encoding one type of capsule with genes encoding
for another is referred to as serotype or capsular switching (Wyres
et al., 2013a). Although capsular switching is not an unusual occur-
rence in pneumococcal biology, the primary concern lies in the VT-
to-NVT capsular switches because of the potential for strains that
cause invasive diseases to evade limited-valency vaccines and
become more virulent.
Vaccine escape recombinants emerged after the introduction of
PCV7, exempliﬁed by the case of ST 320 described above. The ﬁrst
record of ST 320 exhibiting a 19A capsule in the MLST database
(www.mlst.net) is from South Korea in 1998, in other words well
prior to the implementation of PCV7 in the US in 2000. Several
years after PCV7 was ﬁrst used, surveillance programs showed that
this novel 19A variant and its descendants have successfully
spread in many parts of the US as well as in other continents
(Ansaldi et al., 2011; Golubchik et al., 2012). ST 320 is not the only
example of VTs switching to NVTs and surviving into the post-vac-
cine era. PMEN1 (ST 81), initially a 23F clone, has also produced
19A variants, the genomes of some of which have been determined
along with multiple other capsular switching events (Croucher
et al., 2011). Additionally ST 695, yet another 19A clone, was pro-
duced from a serotype 4 ancestor targeted by PCV7 and became
increasingly often isolated from carriage and disease. Similar out-
comes were also reported for other serotypes (Croucher et al.,
2011; Everett et al., 2012; Hu et al., 2012). The properties of the
novel recombinant strains produced by capsular switching may
be quite different from their ancestors, and not necessarily easy
to predict. For example, a recent experimental study of switch vari-
ants with a serotype 6A background carrying a 6C capsule showed
that the new recombinants can acquire enhanced virulence in an
animal model of otitis media (Sabharwal et al., 2013). Although
the implementation of PCV13 is expected to reduce the prevalence
of 19A, the remaining 80 non-vaccine serotypes provide a ready
pool of antigenic diversity that the vaccine will be unable to affect
and which may allow VTs to survive. In other words, recombina-
tion can result to lineages surviving PCV introduction that will be
NVT by deﬁnition, but their genetic background will be that of ear-
lier VTs.
The capsular switch from serotype 4 that produced the 19A var-
iant of ST 695 was also associated with the simultaneous transfer
of multiple DNA fragments from other parts of the genome, some
of which are as long as 44 kb (Golubchik et al., 2012; Wyres
et al., 2013a). This means that multiple genes can be acquired in
a single step. For example, the capsular locus is in close proximity
to the penicillin binding protein genes pbp2x and pbp1a, and so
resistance can be acquired along with a new capsule (Golubchik
et al., 2012; Trzcin´ski et al., 2004; Wyres et al., 2013a). For the
novel 19A variant, a single recombination event led to the switch-
ing of the capsule locus as well as with non-susceptibility to pen-
icillin (Brueggemann et al., 2007). Although capsular switching
appears to be a common enough feature of pneumococci to have
been widespread prior to vaccination (and probably antibiotic
use) (Wyres et al., 2013a), uncertainty over the evolution of thesenovel recombinant serotypes remains a concern. Through recombi-
nation, the pneumococcal population exhibits a large amount of
standing variation such that, as we introduce new interventions,
there is a good chance that a genotype capable of resisting them
is already present, even if rare. Other resident streptococci, such
as encapsulated and/or drug resistant S. mitis, can also contribute
to this variation.3.4. Emergence and spread of multi-drug resistant pneumococci
Antibiotic resistance in pneumococci is widespread, with
numerous clones identiﬁed that have acquired resistance on sepa-
rate occasions (McGee et al., 2001), and selective pressures due to
vaccination can change resistance patterns temporally and geo-
graphically (McCormick et al., 2003). An excellent example of this
is the increased prevalence of penicillin-nonsusceptible pneumo-
cocci (PNSP) among NVT (Gertz et al., 2010; Gherardi et al.,
2012). The pool of pbp genes capable of conferring diminished sus-
ceptibility to penicillin in pneumococci is large and diverse, largely
as a result of a history of extensive recombination that includes loci
originating from other species (Hakenbeck et al., 2012; Izdebski
et al., 2008).
Other factors are also known to inﬂuence the rapid emergence
and evolution of resistance in pneumococcal populations. Horizon-
tal transfer involving mobile elements has led to increasing rates of
macrolide resistance in pneumococci, as exempliﬁed by the macro-
lide-resistant ST 320, carrying the mefE and ermB genes, both of
which are carried by the transposon Tn2010 (Bowers et al., 2012;
Croucher et al., 2013). Changes in the frequencies of speciﬁc sero-
types following PCV immunization can also affect patterns of anti-
biotic resistance. In the United States, changes in the sequences of
resistance determinants against macrolides and b-lactams
occurred after PCV7 introduction (Bowers et al., 2012; Moore
et al., 2008; Pelton et al., 2007). For some pneumococcal lineages,
multidrug resistance and exceptional levels of genetic diversity
arise through ‘soft’ selective sweeps in response to a change in
selection pressure, as was observed in the highly resistant PMEN14
after PCV7 introduction. Soft selective sweeps result from selection
on standing diversity (Hermisson and Pennings, 2005), or migra-
tion importing multiple beneﬁcial alleles (Pennings and
Hermisson, 2006). In soft selective sweeps multiple adaptive
alleles sweep across the population at the same time, in contrast
to hard selective sweeps wherein only a single adaptive allele
spreads (Messer and Petrov, 2013). Multiple adaptive alleles in a
soft selective sweep are derived from different independent ori-
gins, resulting in an extensive pool of standing genetic variation
and greater preservation of the ancestral diversity (Croucher
et al., 2014a).
The long term use of conjugate vaccines is expected to lead to
successive rounds of serotype replacement, unless a formulation
can be arrived at that contains all the more than 90 distinct capsu-
lar types. The alternative is to develop vaccines based on protein
antigens that will target any pneumococcal strain regardless of
its capsule type, although protein antigens are also genetically var-
iable and subject to the same evolutionary processes including
recombination as the capsule. However, the use of different anti-
gens in vaccine development will greatly improve control strate-
gies of pneumococcal diseases. This relies on genomic
approaches that will provide valuable insights into the diversity
and evolution of different molecular targets for protective immu-
nity. Genomics can also provide a more profound understanding
of the range in variation in adapting to antibiotics by different
pneumococcal lineages and how we can potentially manipulate
this variation to reduce the potential for multidrug resistance.
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pneumococci
Nontypeable pneumococci (NTPn) fall into several categories
(Salter et al., 2012): those that do not possess capsule genes
(Hanage et al., 2006; Marsh et al., 2010), pneumococci that are
phenotypically non-encapsulated but possess down-regulated or
defective capsule genes (Hathaway et al., 2004), and a population
of atypical non-encapsulated isolates that are genetically divergent
from most pneumococci (Ing et al., 2012; Rolo et al., 2013). Non-
encapsulated pneumococci are plainly a successful part of the car-
riage population (Chewapreecha et al., 2014; Marsh et al., 2010)
but have also been reported in mucosal infections and conjunctivi-
tis (Haas et al., 2011) as well as rare cases of invasive disease (Scott
et al., 2012b). These NTPn variants are also highly diverse, with
some strains having a widespread inter-continental distribution.
Some NTPn isolates in Brazil were found to be genetically similar
to the global, PNSP clone Spain 9V-3 (Andrade et al., 2010). A line-
age of true NTPn isolated from carriage was reported to have been
found in different continents (Hanage et al., 2006) and subsequent
studies have designated this as the clone NorwayNTST344 (Simões
et al., 2011). In the genome analyses with the highest number of
NTPn sequenced, NTPn were the most prevalent capsule pheno-
type group, out of the more than 3000 carriage isolates sampled
in their study (Chewapreecha et al., 2014). One lineage of NTPn
forms one of the biggest clusters in their sample group, while many
others are distributed within encapsulated pneumococcal clusters.
This study highlights the remarkable diversity of NTPn in pneumo-
coccal populations that remains poorly recognized and
characterized.
The lack of capsule has been shown to facilitate colonization of
the nasopharynx through enhanced adherence to epithelial cells
and bioﬁlm formation (Domenech et al., 2009; Marks et al.,
2012). Recently, some isolates have been found to possess novel
and/or alternative capsule-independent survival mechanisms. Of
noteworthy example is the ﬁnding that some NTPn isolates have
been reported to possess enhanced binding to epithelial cells via
a pspK-dependent mechanism (Keller et al., 2013; Park et al.,
2012). These do not appear to be a transient subpopulation in car-
riage isolates; rates of colonization and adherence are comparable
between them and encapsulated isolates (Keller et al., 2013; Park
et al., 2012). Interestingly, pspK is located at and has replaced the
capsule locus, and recombination of ﬂanking homologous genes
has the potential to spread this gene between encapsulated and
non-encapsulated isolates.
Sporadic or random switching between encapsulated and non-
encapsulated states may play an important role in pneumococcal
population dynamics and antibiotic resistance. Frequent loss and
subsequent gain of capsule loci may partly explain the observed
variation in recombination rates and antibiotic resistance among
pneumococcal lineages. A possible model is illustrated schemati-
cally in Fig. 1. Consider a group of closely related encapsulated
strains at time 1 (t1). By chance, one strain (labeled C) loses its abil-
ity to produce a capsule through gene loss, deletion or insertion of
a stop codon within the capsule locus at t2. Capsule gene loss may
be caused by a single nucleotide polymorphism or indel that can
lead to a nonsynonymous substitution, or a transposon insertion.
As noted above, the capsule is not an absolute requirement for car-
riage or transmission, and so the strain persists in a non-encapsu-
lated state in which it exhibits a higher transformation efﬁciency
(Chewapreecha et al., 2014; Pearce et al., 2002; Weiser and
Kapoor, 1999) and subsequently acquires exogenous DNA, includ-
ing potential virulence and resistance genes at a higher rate than
its encapsulated relatives. The strain may eventually regain its ori-
ginal capsule type or another capsule of a different serotype (t3).Once the capsule has been regained, the result will be variation
in recombination rates even at unlinked loci among them, as has
been observed (Hanage et al., 2009), and which may also correlate
with increased resistance for strain C that previously lacked a
capsule.
Since recombination is an important mechanism to generate
genomic variation in response to selective pressures from the envi-
ronment, it is likely that the environment can lead to signiﬁcant
changes in capsule production in pneumococcus. Oxygen concen-
tration in the environment has been reported to inﬂuence capsule
production (Weiser et al., 2001). More recently, Carvalho et al.
reported that inactivation of the gene coding for pyruvate oxidase
resulted to enhanced capsule production (Carvalho et al., 2013).
The authors proposed that this enzyme acts as a sensor of oxygen
levels in the environment to signal the pneumococcus to deter-
mine the amount of capsule it needs to produce (Carvalho et al.,
2013).
5. The role of mobile elements and phages in pneumococcal
evolution
Mobile elements and phages play an important role in pneumo-
coccal evolution, both as a selective pressure and as an additional
means of mobilizing genetic material. Integrative conjugative ele-
ments (ICEs) are autonomously mobile entities that can be excised
and subsequently integrated into the genome within the same cell
at a different location or in a new host cell. These elements are
transferred mainly through conjugation between cells. The
Tn5253 and Tn916 ICE families are commonly found in pneumo-
coccus and are important vehicles for the dissemination of antibi-
otic resistance in pneumococci and between Streptococcus species
(Roberts and Mullany, 2011). The ICE family of Tn916 is transmis-
sible in many Gram-positive bacteria and can therefore easily
mobilize genetic elements from diverse sources. These transposons
are particularly known for carrying and transferring the tetracy-
cline resistance determinant tet(M). Some Tn916-like elements
also carry other resistance genes, such as erm(B)-mediated eryth-
romycin resistance, and genes associated with other accessory
functions (Cochetti et al., 2007). Genomic studies of the highly suc-
cessful PMEN1 clone showed a diverse array of Tn916-like ele-
ments contributing to its extensive antibiotic resistant phenotype
(Croucher et al., 2011; Domenech et al., 2013). The persistence of
antibiotic resistance for many years may also be attributed to ICEs,
as in the case of Tn916 elements from pneumococci dated between
1967 and 1972 that exhibit high similarity to the Tn916 circulating
in pneumococcal populations today (Wyres et al., 2013b). The rea-
son why these elements should be so conserved is not clear, but
the lack of variation is in marked contrast with other ICE (Wyres
et al., 2013b).
Tn5253 and its relatives are large composite transposons con-
sisting of Tn5252 and a Tn916-like Tn5251 (Ayoubi et al., 1991;
Iannelli et al., 2014). Although the majority of the ORFs in
Tn5253 are of unknown function (Iannelli et al., 2014), Tn5252 is
known to possess a chloramphenicol resistance gene (cat). Hence,
because of the composite nature of Tn5253, resistance to both tet-
racycline and chloramphenicol can be easily disseminated in bac-
terial populations. Tn5253-like elements in pneumococci are also
extremely diverse in gene content (Henderson-Begg et al., 2009;
Mingoia et al., 2011), further expanding their genetic repertoire.
Bacteriophages also play an important role in pneumococcal
evolution and pathogenicity by rapidly disseminating genetic
material, as in the case of the PMEN1 lineage discussed previously,
which carries a 39.1 kb intact prophage and a 6.4 kb prophage rem-
nant (Croucher et al., 2009). Comparative analyses of ten temper-
ate pneumococcal phages also indicate the presence of different
Fig. 1. Switching between encapsulated and non-encapsulated states in a closely related group of pneumococci. Labels A–E represent different strains. Different capsule
colors indicate different serotypes. tn indicates point in time. Colored arrows represent different genes. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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between phages (Romero et al., 2009). Hence, phage-mediated
recombination can signiﬁcantly enhance the genetic diversity
and ability of the pneumococcus to evade selection pressures.
The contributions of ICEs and phages to pneumococcal biology
and pathogenicity further highlight the remarkable ability of these
bacteria to exchange genes through different transfer mechanisms
(transformation, transduction and conjugation). However, the
diversity of these pneumococcal mobile elements and phages has
not been fully explored and remain under-appreciated. We antici-
pate that genome sequencing of pneumococcal samples from
diverse geographical origins will provide additional insight into
the extent of the genetic diversity of ICEs and phages, and how
these combine with other loci to make up the accessory genome
of pneumococci.6. Conclusions and future directions
Genomic data can offer unprecedented resolution in the under-
standing of pathogen evolution, adaptation and pathogenicity. For
pneumococcus, this approach has been especially informative in
deﬁning how the pathogen responds to interventions such as anti-
biotic use or conjugate vaccination, and can better inform us of the
likely consequences of variation among different pneumococcal
lineages in the face of any new selective pressure. Moreover, geno-
mic studies have given us a deeper insight into the contributions of
genetic exchange as a driving factor in pneumococcal evolution
and as a mechanism for evading selection pressures.
The use of a population genomic dataset is also crucial in iden-
tifying the association of clusters of orthologous genes (COGs) with
speciﬁc environments, such as speciﬁc host characteristics (age,
immunosuppression, antibiotic consumption, temporal association
with other respiratory bacterial or viral diseases) and geography.
The precise COGs found in any population in question may greatly
vary under different ecological conditions. The implications of
these changes, particularly in light of the re-structuring of pneu-
mococcal populations in response to clinical interventions, remain
unclear. For example, the composition of the core genome may
likely reﬂect the resulting niche differentiation that would result
in strains adapted to particular host characteristics, as has been
suggested for antigen COGs that were stably associated withspeciﬁc genotypes and host ages (Croucher et al., 2013). Although
this line of investigation is still in its infancy, we can expect that
such information will be vital in understanding the ecological
aspects of pneumococcal pathogenicity. Recent work has shown
that the relationship between SNP divergence in the ‘core’ genome
and divergence in gene content, at least in the population studied
in (Croucher et al., 2013), is approximately linear (Croucher et al.,
Nature Communications, in press). This work also shows that the
major lineages previously identiﬁed are approximately equidistant
in terms of how much they differ in gene content. How homolo-
gous recombination and other processes, such as phage or conjuga-
tive elements, combine to produce this pattern is presently
unclear.
Although it can be argued that the core genome should not
include any niche-speciﬁc genes, the deﬁnition of the core genome
of any microbial population will vary depending on the number
and/or identity of strains included, sampling scheme and the eco-
logical setting on which the populations rests, and may therefore
include adaptive and niche-speciﬁc genes. Thus, the core genome
is not an inﬂexible property of a population, although it encounters
the same evolutionary processes as the accessory genome.
Continued surveillance is critical as novel genotypes can emerge
from obscurity and exhibit characteristics that are poorly under-
stood. Likewise, a more profound understanding of the evolution,
geographic distribution and transmission of multi-drug resistant
strains can also be attained with genomics (Croucher et al.,
2014a,b, 2013, 2011). Population genomic approaches at different
spatial and temporal scales are a valuable tool to enhance our abil-
ity to detect cryptic outbreaks and to trace the origins and historical
patterns of spread, thereby improving our current strategies in con-
trolling this global pathogen as well as other pathogenic species of
this genus. The present challenge is combining genomics with rig-
orous experimental methods and to ask how we can robustly link
observed genomic variation to phenotype. This is the work of the
next few years, and will be the fruit of the systematic application
of evolutionary biology and genomic methods.Acknowledgements
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